Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1801 participants.

Also called NCT04001504

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,801 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT04001504
Other papers using this trial's data
  • Influenza vaccination for prevention of death and major cardiovascular events in patients with a history of stroke: A subanalysis of the VIP-ACS trial International journal of stroke : official journal of the International Stroke Society, 2026-04 DOI, PubMed 40973981
  • Influenza vaccination strategy in acute coronary syndromes: the VIP-ACS trial European heart journal, 2022-11-01 DOI, PubMed 36030400

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04001504. Randomized; single masking; primary purpose treatment. Start 2019-07-19 (actual); primary completion 2022-08-28 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Vaccination Against Influenza to Prevent Cardiovascular Events After Acute Coronary Syndromes
Acronym
VIP-ACS
Condition
Acute Coronary Syndrome
Intervention (Biological)
Double Dose Quadrivalent Influenza Vaccine
Intervention (Biological)
Standard Dose Quadrivalent Influenza Vaccine
Lead sponsor
Hospital Israelita Albert Einstein (class: other)
Collaborator
Ministry of Health, Brazil (class: other government)

Record details

Record id
cardio:ct-nct04001504
Content hash
0f30214a57530a02753181ad99db21bedb945ef47f8bae844f5f4ec28b9e6a59